Posted by Michael Wonder on 27 Feb 2017
AbbVie receives CHMP positive opinion for eight week treatment option with Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for patients with genotype 1b chronic hepatitis C
27 February 2017 - CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of Viekirax + Exviera for previously untreated genotype 1b chronic hepatitis C virus patients with minimal to moderate fibrosis.
AbbVie announced today that the CHMP of the EMA has granted a positive opinion for a shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with genotype 1b chronic hepatitis C virus and minimal to moderate fibrosis.
Viekirax + Exviera is currently approved in the European Union for use as a 12-week treatment for genotype 1b chronic hepatitis C virus infected patients without cirrhosis or with compensated cirrhosis.
